Popular Trials
Monoclonal Antibodies
BI 764532 for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Los Angeles, California
This trial is for adults with advanced small-cell lung cancer & neuroendocrine tumours. It tests 2 doses of BI 764532, an antibody-like molecule, to see if it shrinks tumours & is safe & tolerable. Participants visit the study site regularly to monitor safety & record effects.
ATR Kinase Inhibitor
Berzosertib + Radiation for Brain Metastases from Lung Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is testing the side effects and best dosage of a new drug, berzosertib, when given with whole brain radiation therapy, for patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread to the brain.
Angiogenesis Inhibitor
Cediranib + Olaparib for Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing a combination of two drugs to treat patients with solid tumors. Cediranib maleate blocks enzymes needed for cell growth, and olaparib may make the tumor more sensitive to Cediranib maleate.
Popular Filters
Trials for NSCLC Patients
PLK-1 Inhibitor
Onvansertib for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing onvansertib, a drug that blocks an enzyme helping cancer cells grow, in patients with small cell lung cancer who can't use standard chemotherapy. By stopping the cancer cells from repairing themselves, the drug aims to slow down or stop their growth.
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Photosensitizer
Photodynamic Therapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial studies a treatment where a special drug is injected and then activated by a laser to shrink tumors in lung cancer patients whose cancer has spread. The goal is to see if this method can safely reduce tumor size.
Trials for Non-Small Cell Lung Cancer Patients
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Photosensitizer
Photodynamic Therapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial studies a treatment where a special drug is injected and then activated by a laser to shrink tumors in lung cancer patients whose cancer has spread. The goal is to see if this method can safely reduce tumor size.
Monoclonal Antibodies
SGN-CEACAM5C for Advanced Cancers
Recruiting1 awardPhase 1
Grand Rapids, Michigan
This trial is testing a new drug called SGN-CEACAM5C for patients with hard-to-treat solid tumors that have either returned or didn't respond to standard treatments. The drug targets cancer cells and kills them. The study will determine the safe dosage and effectiveness of the drug.
Mitotic Inhibitor
ADI-PEG 20 + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Saint Louis, Missouri
This trial tests a combination of three drugs to treat lung cancer patients who did not respond to initial treatments. The drugs work by starving the cancer cells and attacking them with chemotherapy.
Trials for Metastatic Patients
Chemotherapy
Immunotherapy + Chemotherapy for Small Cell Lung Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial tests a new combination of immunotherapy and chemotherapy for patients with advanced lung cancer. The treatment uses two drugs to help the immune system fight cancer, along with standard chemotherapy to kill cancer cells. Researchers hope this new approach will improve survival compared to existing treatments.
PD-1/PD-L1 Inhibitor
Pembrolizumab Combinations for Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Richmond, Virginia
This trial tests a combination of pembrolizumab and new experimental drugs in patients with advanced lung cancer who did not respond to previous treatments. The goal is to see if this combination is safe and effective. Pembrolizumab helps the immune system attack cancer by blocking a protein that stops immune cells from working. Pembrolizumab has been widely studied and approved for the treatment of various cancers, including lung cancer.
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Trials for EGFR Positive Patients
Mitotic Inhibitor
ADI-PEG 20 + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Saint Louis, Missouri
This trial tests a combination of three drugs to treat lung cancer patients who did not respond to initial treatments. The drugs work by starving the cancer cells and attacking them with chemotherapy.
Checkpoint Inhibitor
Immunotherapy + Radiation for Advanced Lung Cancer
Recruiting1 awardPhase 1
Chicago, Illinois
This trial is designed to study whether nivolumab/ipilimumab plus either sequential or concurrent stereotactic body radiotherapy (SBRT) is safe for patients with stage IV non-small cell lung cancer.
Tyrosine Kinase Inhibitor
Erlotinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Trials for ALK Positive Patients
Mitotic Inhibitor
ADI-PEG 20 + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Saint Louis, Missouri
This trial tests a combination of three drugs to treat lung cancer patients who did not respond to initial treatments. The drugs work by starving the cancer cells and attacking them with chemotherapy.
Checkpoint Inhibitor
Immunotherapy + Radiation for Advanced Lung Cancer
Recruiting1 awardPhase 1
Chicago, Illinois
This trial is designed to study whether nivolumab/ipilimumab plus either sequential or concurrent stereotactic body radiotherapy (SBRT) is safe for patients with stage IV non-small cell lung cancer.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Tyrosine Kinase Inhibitor
Erlotinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Phase 3 Trials
Chemotherapy
Immunotherapy + Chemotherapy for Small Cell Lung Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial tests a new combination of immunotherapy and chemotherapy for patients with advanced lung cancer. The treatment uses two drugs to help the immune system fight cancer, along with standard chemotherapy to kill cancer cells. Researchers hope this new approach will improve survival compared to existing treatments.
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Immunotherapy for Small Cell Lung Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial is testing whether Durvalumab alone or with Tremelimumab can help patients with a specific type of lung cancer who have already had initial treatment. The drugs aim to boost the immune system to fight off any remaining cancer cells. Durvalumab and Tremelimumab are being studied together for their potential to improve cancer treatment outcomes.
Checkpoint Inhibitor
Radiation Therapy + Atezolizumab for Small Cell Lung Cancer
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial will compare the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab (a monoclonal antibody) versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage).
Trials With No Placebo
PLK-1 Inhibitor
Onvansertib for Small Cell Lung Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing onvansertib, a drug that blocks an enzyme helping cancer cells grow, in patients with small cell lung cancer who can't use standard chemotherapy. By stopping the cancer cells from repairing themselves, the drug aims to slow down or stop their growth.
PD-1/PD-L1 Inhibitor
Pembrolizumab Combinations for Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Richmond, Virginia
This trial tests a combination of pembrolizumab and new experimental drugs in patients with advanced lung cancer who did not respond to previous treatments. The goal is to see if this combination is safe and effective. Pembrolizumab helps the immune system attack cancer by blocking a protein that stops immune cells from working. Pembrolizumab has been widely studied and approved for the treatment of various cancers, including lung cancer.
Small Molecule
PC14586 for Solid Tumors
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Photosensitizer
Photodynamic Therapy for Lung Cancer
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial studies a treatment where a special drug is injected and then activated by a laser to shrink tumors in lung cancer patients whose cancer has spread. The goal is to see if this method can safely reduce tumor size.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.